A Phase 1 interventional study of SHR-1918 and SHR-1918 placebo in Hyperlipemia, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-06.
Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 1 of them phase 3. Hyperlipidemias · Jiangsu HengRui Medicine Co., Ltd..
Among the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 8 in phase 1, and was the 3rd registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →3 of the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–79
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 18+
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 5 · Phase 3 1
First in 2019; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 78 across the 14 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Beijing Suncadia Pharmaceuticals Co., Ltd, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Beijing Suncadia Pharmaceuticals Co., Ltd is the lead sponsor of 25 studies on the registry; 9 are open to participants now.
1 of the studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07230730Phase 3Beijing Suncadia Pharmaceuticals Co., LtdA Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918 injection in healthy subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
1.History of disease or treatment for:
2.Any one of the following tests at screening :
3.General:
4.The Investigator determines that the subjects have poor compliance or have any factors that may prevent them from participating in the study, including, but not limited to, the study placing the subjects at unacceptable risk or possibly interfering with the study results.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 6 cohorts of healthy subjects will receive a single dose of SHR-1918 injection
Drug: SHR-1918
Up to 6 cohorts of healthy subjects will receive a single dose of SHR-1918 placebo injection
Drug: SHR-1918 placebo
Ascending dose
Ascending dose
To assess the number of subjects with adverse events (AEs)
Time frame: up to day 190
To assess the number of subjects with serious adverse events (SAEs)
Time frame: up to day 190
To assess AUC0-t
Time frame: up to day 190
To assess AUC0-∞
Time frame: up to day 190
To assess Tmax
Time frame: up to day 190
To assess Cmax
Time frame: up to day 190
To assess t1/2
Time frame: up to day 190
To assess CL/F
Time frame: up to day 190
To assess 、V/F.
Time frame: up to day 190
To assess LDL-C
Time frame: up to day 190
To assess TC
Time frame: up to day 190
To assess HDL-C
Time frame: up to day 190
To assess TG
Time frame: up to day 190
To assess ApoB
Time frame: up to day 190
To assess ApoA1
Time frame: up to day 190
To assess Lp(a)
Time frame: up to day 190
To assess VLDL-C.
Time frame: up to day 190
To assess ADA(or/and Nab).
Time frame: up to day 190
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Dec 2023, 17 months after the start.
Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's planned 17 months is above that.
Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR-1918
Beijing Suncadia Pharmaceuticals Co., Ltd →